KalVista Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US4834971032

SecurityKALV / KalVista Pharmaceuticals, Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership244,261 shares
Latest Disclosed Value $ 4,916,974
Citigroup Inc reports 2,167.77% increase in ownership of KALV / KalVista Pharmaceuticals, Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 244,261 shares of KalVista Pharmaceuticals, Inc. (US:KALV) valued at $4,916,974 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 10,771 shares of KalVista Pharmaceuticals, Inc.. This represents a change in shares of 2,167.77% during the quarter. The current value of the position is $6,582,834 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 244,261 233,490 2,167.77 4,917 2,741.62 0.0021
2026-02-13 2025-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 10,771 -269,885 -96.16 174 -94.94 0.0001
2025-11-10 2025-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 280,656 -18,538 -6.20 3,418 1.06 0.0015
2025-08-11 2025-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 299,194 150,967 101.85 3,382 97.78 0.0017
2025-05-12 2025-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 148,227 -179,069 -54.71 1,711 -38.31 0.0009
2025-02-12 2024-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 327,296 21,792 7.13 2,772 -21.63 0.0016
2024-11-12 2024-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 305,504 19,440 6.80 3,538 4.99 0.0020
2024-08-12 2024-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 286,064 3,181 1.12 3,370 0.45 0.0022
2024-05-10 2024-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 282,883 974 0.35 3,355 -2.87 0.0022
2024-02-09 2023-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 281,909 4,991 1.80 3,453 29.52 0.0024
2023-12-06 2023-09-30 13F/A-1 KALVISTA PHARMACEUTICALS COM 483497103 276,918 -22,890 -7.63 2,667 -1.19 0.0020
2023-11-09 2023-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 276,918 -22,890 2,667 0.0020
2023-08-10 2023-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 299,808 22,902 8.27 2,698 23.99 0.0018
2023-05-11 2023-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 276,906 -165 -0.06 2,176 16.24 0.0015
2023-02-09 2022-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 277,071 276,402 41,315.70 1,873 18,620.00 0.0015
2022-11-10 2022-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 669 -1,478 -68.84 10 -52.38 0.0000
2022-08-10 2022-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 2,147 -6,290 -74.55 21 -83.06 0.0000
2022-05-12 2022-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 8,437 -45,690 -84.41 124 -82.68 0.0001
2022-02-10 2021-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 54,127 25,139 86.72 716 41.50 0.0004
2021-11-10 2021-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 28,988 -68,829 -70.37 506 -78.41 0.0003
2021-08-10 2021-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 97,817 73,132 296.26 2,344 269.72 0.0014
2021-05-13 2021-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 24,685 21,109 590.30 634 832.35 0.0004
2021-02-11 2020-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 3,576 2,658 289.54 68 466.67 0.0000
2020-11-12 2020-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 918 -1,362 -59.74 12 -57.14 0.0000
2020-08-12 2020-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 2,280 -1,607 -41.34 28 -6.67 0.0000
2020-05-12 2020-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 3,887 1,357 53.64 30 -33.33 0.0000
2020-02-12 2019-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 2,530 1,951 336.96 45 650.00 0.0000
2019-11-08 2019-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 579 -2,681 -82.24 6 -91.67 0.0000
2019-08-12 2019-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 3,260 -8,978 -73.36 72 -79.43 0.0001
2019-05-13 2019-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 12,238 12,238 350 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.